---

Kurzfassung

This invention provides a safe Epstein-Barr Virus vaccine, which does not introduce chromosomal instabilities associated with cancer development.

---

Hintergrund

Experts estimate that an EBV vaccine could prevent 2% of all cancer cases worldwide.

---

Problemstellung

Until now no method for producing a safe and efficient vaccine against EBV has been devel-oped.

---

Lösung

This vaccine uses “virus-like particles” (VLP), devoid of detectable genetic material, to mimic an EBV infectious particle. While these particles prompt the body to mount an immune response they are themselves innoc-uous, thus making the vaccine much safer.

---

Vorteile

This vaccine lacks the ability of EBV particles to induce chromosome instability and chromo-somal associated with cancer development. In particular, EBV particles in this vaccine do not enter the cytosol and/or nucleus of cells, mak-ing it significantly safer than existing alterna-tives.

---

Anwendungsbereiche

Prevention from EBV disease

---

Service

Convincing in vitro and in vivo data are avail-able showing the absence of chromosomal instability after treatment with the new genera-tion VLP. Animal studies looking at safety and efficacy of the VLPs are currently being con-ducted.